Evaluating the AltaValve as a novel method for transcatheter mitral valve replacement.

Mitral regurgitation (MR) is the most common heart valve disease, and severe MR is associated with a poor prognosis if left untreated. Although surgical repair or replacement constitutes the standard therapy when indicated, many high-risk patients are considered ineligible for surgery. Transcatheter mitral valve replacement (TMVR) offers a less invasive alternative to conventional surgery and may also overcome some of the limitations of percutaneous repair techniques. Currently, multiple TMVR devices are undergoing clinical evaluation, showing promising results. However, challenges mainly related to the complex mitral valve anatomy along with the interaction with the left ventricular outflow tract (LVOT) have resulted in high screen failure rates among TMVR candidates. The AltaValve System features a supra-annular design, ensuring secure fixation in the left atrium above the native mitral valve annulus without anchoring mechanisms that could interfere with the left ventricle (LV). These distinctive attributes aim to address the existing TMVR limitations across a broad patient population and help to avoid complications such as LVOT obstruction, LV damage, and/or prosthesis embolization. Initial safety and feasibility data are encouraging, but a larger cohort of patients with longer follow-up will be essential to confirm the safety and efficacy of the AltaValve system.